Eagle Health Investments LP Invests $4.91 Million in uniQure N.V. $QURE

Eagle Health Investments LP purchased a new position in shares of uniQure N.V. (NASDAQ:QURE) in the fourth quarter, Holdings Channel.com reports. The fund purchased 205,247 shares of the biotechnology company’s stock, valued at approximately $4,912,000. uniQure makes up about 1.1% of Eagle Health Investments LP’s portfolio, making the stock its 22nd biggest position.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure during the 3rd quarter worth approximately $50,000. Torren Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth approximately $28,000. FNY Investment Advisers LLC increased its holdings in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the last quarter. Finally, IFP Advisors Inc acquired a new stake in shares of uniQure during the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on QURE shares. HC Wainwright cut their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Wolfe Research initiated coverage on shares of uniQure in a report on Monday, February 23rd. They set a “peer perform” rating for the company. TD Cowen reiterated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

uniQure Stock Down 0.4%

uniQure stock opened at $24.60 on Thursday. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm has a 50 day moving average price of $18.94 and a 200 day moving average price of $22.33. The company has a market capitalization of $1.55 billion, a PE ratio of -7.07 and a beta of 0.87.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Research analysts expect that uniQure N.V. will post -3.68 earnings per share for the current year.

Insider Activity at uniQure

In related news, insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the sale, the insider owned 169,669 shares in the company, valued at approximately $4,251,905.14. This trade represents a 20.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the sale, the chief financial officer owned 226,581 shares of the company’s stock, valued at $2,052,823.86. This trade represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 94,396 shares of company stock worth $1,850,434 over the last quarter. Company insiders own 4.79% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.